Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$0.82
-3.8%
$1.00
$0.66
$2.10
$202.30M1.49548,720 shs243,375 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.97
-7.5%
$1.12
$0.71
$2.21
$153.98M2.421.61 million shs1.19 million shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.98
+1.3%
$3.57
$1.98
$4.22
$158.95M1.27131,531 shs137,620 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.47%-0.75%-13.89%-25.47%-21.17%
InflaRx N.V. stock logo
IFRX
InflaRx
-6.19%+17.96%+115.91%+134.52%+19.39%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.00%-1.24%+16.37%+16.37%+72.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$0.82
-3.8%
$1.00
$0.66
$2.10
$202.30M1.49548,720 shs243,375 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.97
-7.5%
$1.12
$0.71
$2.21
$153.98M2.421.61 million shs1.19 million shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.98
+1.3%
$3.57
$1.98
$4.22
$158.95M1.27131,531 shs137,620 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.47%-0.75%-13.89%-25.47%-21.17%
InflaRx N.V. stock logo
IFRX
InflaRx
-6.19%+17.96%+115.91%+134.52%+19.39%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.00%-1.24%+16.37%+16.37%+72.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.00
Hold$16.501,912.69% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.50
Moderate Buy$5.80194.42% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest IFRX, ORMP, and ENLV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Initiated CoverageOutperform$7.00 ➝ $5.00
4/21/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Reiterated RatingBuy$14.00
4/7/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Boost Price TargetBuy$13.00 ➝ $20.00
3/27/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Reiterated RatingSell (D-)
3/27/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
Reiterated RatingHold (C)
3/20/2026
InflaRx N.V. stock logo
IFRX
InflaRx
Lower Price TargetBuy$22.00 ➝ $14.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$8.15 per shareN/A
InflaRx N.V. stock logo
IFRX
InflaRx
$30K4,747.04N/AN/A$0.65 per share3.03
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M80.50$0.09 per share43.32$5.02 per share0.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/A
InflaRx N.V. stock logo
IFRX
InflaRx
-$51.63M-$0.76N/AN/AN/AN/A-80.51%-61.36%5/7/2026 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$64.05M$1.492.67N/AN/AN/A-6.83%-6.25%N/A

Latest IFRX, ORMP, and ENLV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.17N/AN/AN/A$0.01 millionN/A
3/27/2026Q4 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.08-$0.06+$0.02$0.24$0.50 millionN/A
3/20/2026Q4 2025
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.17-$0.17N/A-$0.18$0.03 million($0.04) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.256.28%N/A16.78%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
193.24
193.24
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
4.13
4.13
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
6.98
6.98

Institutional Ownership

CompanyInstitutional Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%

Insider Ownership

CompanyInsider Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
17.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
70237.38 million208.23 millionOptionable
InflaRx N.V. stock logo
IFRX
InflaRx
6072.29 million60.51 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.45 million33.25 millionOptionable

Recent News About These Companies

Oramed Pharmaceuticals Incorporated
Oramed: Q4 Earnings Snapshot
Oramed and Lifeward Announce Strategic Transaction

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$0.82 -0.03 (-3.80%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$0.82 +0.00 (+0.02%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$1.97 -0.16 (-7.51%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$1.98 +0.01 (+0.25%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$3.98 +0.05 (+1.27%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$4.03 +0.05 (+1.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.